NewsBenzingaLegend Biotech Reports 50% Of CARTITUDE-2 Patients Remained Progression-Free At 5 Years After Single CARVYKTI Infusion Legend Biotech Reports 50% Of CARTITUDE-2 Patients Remained Progression-Free At 5 Years After Single CARVYKTI Infusion Benzinga 2026.09.25 11:03 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on PENN Entertainment, Lowers Price Target to $22 HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target Alphabet Stock Rises: What's Going On? $1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today Wells Fargo Maintains Equal-Weight on MGM Resorts International, Lowers Price Target to $29 Why Is Applied Digital Stock Surging on Monday?
